Benjamin Martin

Benjamin Martin

Auto-generated profile, based on publicly available information

Benjamin Martin

Biomedical Informatics and Data Science The Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Hypertension
Verified
Journal Article
Open access
RBRobert B. Barrett
Robert B. Barrett
BRBenjamin Riesser
Benjamin Riesser
BMBenjamin Martin
Benjamin Martin
NSNeha Sachdev
Neha Sachdev
MRMichael K. Rakotz
Michael K. Rakotz
BEBrent M. Egan
Brent M. Egan
BACKGROUND: Adults with hypertension have fewer cardiovascular events if controlled within the first 6 months of diagnosis, during which time they are excluded from many hypertension control metrics. We compared blood pressure (BP, mm Hg) control rates from 6 to 42 months in adults with hypertension who did or did not have antihypertensive treatment initiated (TI) with monotherapy during the first month after diagnosis, irrespective of subsequent changes in antihypertensive pharmacotherapy. METHODS: A retrospective cohort of 15 422 patients, mean age 56.0±14.8 years, from 5 health care organizations, was identified with previously undiagnosed and untreated hypertension. BP control (<140/<90) and TI on visits with uncontrolled readings were assessed as a function of time since diagnosis, up to 42 months. Logistic regression models provided estimates of the odds of TI for initial BP, stratified by race, sex, and diagnosed diabetes. Cox proportional hazards regression estimated the hazard ratio of BP control over time. RESULTS: Patients with TI during the first month versus later time points had better BP control at 6 (57.7% versus 47.8%, P <0.001) through 30 months (66.8% versus 62.2%, P 30% of patients.

8 June 2010 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
JCJanet Colli
Janet Colli
BMBenjamin Martin
Benjamin Martin
MPMatthew Purcell
Matthew Purcell
YKYoung-Il Kim
Young-Il Kim
EBErik J. Busby
Erik J. Busby

2 June 2026 in Ophthalmology
Verified
Journal Article
Open access
CCCindy X. Cai
Cindy X. Cai
BTBrian Toy
Brian Toy
BMBenjamin Martin
Benjamin Martin
RFRuochong Fan
Ruochong Fan
EWErik Westlund
Erik Westlund
MSMarc A. Suchard
Marc A. Suchard
Or Purpose: To investigate the potential association of semaglutide and neovascular age-related macular degeneration (NVAMD) DESIGN: Retrospective study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network during the study period from 12/1/2017-12/31/2024 SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: Adults with type 2 diabetes (T2D) on semaglutide, other glucagon-like peptide-1 receptor agonists (GLP-1RAs) (dulaglutide, exenatide), or non-GLP-1RAs (empagliflozin, sitagliptin, glipizide) METHODS, INTERVENTION OR TESTING: The association between semaglutide and NVAMD was assessed using two approaches: an active-comparator cohort design and a self-controlled case-series (SCCS) analysis. The cohort design used propensity score-adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The SCCS used conditional Poisson regression models to estimate incidence rate ratios (IRRs). A random-effects meta-analysis was used to generate network-wide HR and IRR estimates. Two definitions of NVAMD, one based on condition codes alone (NVAMD-C) or condition codes and procedures (NVAMD-CP). A total of 227,971 new users of semaglutide were included in the study. The risk of NVAMD among semaglutide users was similar to users of dulaglutide (NVAMD-C HR 0.57, 95% CI 0.21 to 1.57, P=.28; NVAMD-CP HR 0.25, 95% CI 0.05 to 1.27, P=.10), empagliflozin (NVAMD-C HR 0.98, 95% CI 0.54 to 1.79, P=.94; NVAMD-CP HR 0.79, 95% CI 0.38 to 1.64, P=.52), sitagliptin (NVAMD-C HR 2.08, 95% CI 0.90 to 4.83, P=.09; NVAMD-CP HR 1.80, 95% CI 0.55 to 5.86, P=.33), and glipizide (NVAMD-C HR 0.83, 95% CI 0.35 to 2.02, P=0.69; NVAMD-CP HR 0.50, 95% CI 0.21 to 1.19, P=.12). There was no evidence of increased or decreased risk for NVAMD associated with semaglutide exposure (NVAMD-C: incidence rate ratio [IRR] 0.92, 95% CI 0.67 to 1.26, P=.60; NVAMD-CP IRR 1.02, 95% CI 0.76 to 1.36, P=.92) nor any of the other GLP-1RA or non-GLP-1RAs. We detected no differences in the risk of NVAMD associated with semaglutide use among adults with T2D.

15 November 2025 in Arthritis Care & Research
Verified
Journal Article
Closed access
BMBenjamin Martin
Benjamin Martin
WKWill Kelly
Will Kelly
HMHannah Morgan‐Cooper
Hannah Morgan‐Cooper
TFThomas Falconer
Thomas Falconer
EPElizabeth Park
Elizabeth Park
CMChristopher A. Mecoli
Christopher A. Mecoli

1 May 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
SKSeonji Kim
Seonji Kim
JPJimyung Park
Jimyung Park
HCHsin Yi Chen
Hsin Yi Chen
CSChristianus Heru Setiawan
Christianus Heru Setiawan
HLHaeun Lee
Haeun Lee
SSSeung In Seo
Seung In Seo
BACKGROUND: Proton pump inhibitors (PPIs) may potentially reduce clopidogrel’s antiplatelet effect and increase cardiovascular risk. The degree of CYP (cytochrome P450) 2C19 inhibition varies among PPIs. Few studies have evaluated individual PPIs by CYP2C19 inhibition strength across countries. This study aimed to compare the incidence of cardiovascular events between strong CYP2C19-inhibiting potency and weak CYP2C19-inhibiting potency (weak or non-CYP2C19–inhibiting PPIs) in patients receiving clopidogrel. METHODS: We conducted an international observational cohort study using 14 databases from the United States, South Korea, and Taiwan. We included patients aged ≥18 years who received clopidogrel with PPIs from 1985 to 2023. PPIs were classified into strong CYP2C19-inhibiting PPIs and weak or non-CYP2C19–inhibiting PPIs based on CYP2C19 inhibition. We compared the hazard ratios and 95% CIs for major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality, using the Cox proportional hazards model after 1:1 propensity score matching. Secondary outcomes included cardiovascular mortality, myocardial infarction, stroke, and all-cause mortality. A random-effects model calculated pooled hazard ratios and 95% CIs. Only databases meeting all diagnostic criteria were included in the meta-analysis. RESULTS: Large-scale propensity score matching identified 166 005 patient pairs. During the 365-day follow-up, the risk of major adverse cardiovascular events did not differ significantly between patients receiving clopidogrel plus strong CYP2C19-inhibiting PPIs and those receiving clopidogrel plus weak or non-CYP2C19–inhibiting PPIs (17.63 per 1000 person-years versus 16.82 per 1000 person-years; calibrated hazard ratio, 1.00 [95% CI, 0.79–1.26]). No significant difference was observed in the risk of secondary outcomes (calibrated hazard ratio, cardiovascular mortality 1.10 [95% CI, 0.87–1.39], myocardial infarction 0.98 [95% CI, 0.81–1.19], stroke 1.05 [95% CI, 0.87–1.27], and all-cause mortality 1.18 [95% CI, 0.93–1.50]). CONCLUSIONS: Concomitant use of clopidogrel and strong CYP2C19-inhibiting PPIs was not associated with a higher cardiovascular risk compared with concomitant use of clopidogrel and weak or non-CYP2C19–inhibiting PPIs. This large-scale study does not support the clinical significance of potential interactions between PPIs and clopidogrel.

1 March 2005 in European Urology Supplements
Verified
Journal Article
Closed access
JGJ. Gutiérrez-Banos
J. Gutiérrez-Banos
ERE. Rodrigo
E. Rodrigo
HRH. Rebollo
H. Rebollo
JLJorge Lopez-Portillo
Jorge Lopez-Portillo
MCM. Correas
M. Correas
MAM. Arias
M. Arias